Wegovy 0.5 mg/0.5 ml pen: the dose step that matters most

Is 0.5 mg the right next step for you, or should you stay at 0.25 mg longer?

The 0.25 mg starting dose has one job: giving your system time to adjust to semaglutide before the medicine gets to work in earnest. Most people move on after four weeks. The question your prescriber is really answering at that point is not "has 0.25 mg produced weight loss?" (it isn't supposed to yet) but "has the tolerability been manageable enough to go further?"

Moving to 0.5 mg is the standard next step, and for most adults it's straightforward. If nausea, vomiting or other gastrointestinal effects were significant at 0.25 mg, staying on the starter dose for a further four weeks before increasing is a clinically reasonable approach, and you can read more about that period on the Wegovy 0.25 mg/0.5 ml page. That decision belongs to your prescriber, informed by how you actually felt. The full Wegovy dose schedule runs from 0.25 mg through to 2.4 mg (or the newer 7.2 mg pen, where available), 0.5 mg is early in that journey, and there's no clinical benefit in rushing it.

The NHS patient information for semaglutide is clear that dose changes should follow prescriber guidance and the Patient Information Leaflet, not personal preference or impatience for faster results. That's sensible advice. A prescriber who reviews your progress before each step is a safeguard, not a barrier.

What the 0.5 mg pen looks like in practice, and where it fits in the week

Practically, the 0.5 mg/0.5 ml pen works exactly like the 0.25 mg one. It's pre-set, pre-filled, and delivers four doses before it's empty. Same once-weekly injection, same rotation of sites (abdomen, thigh or upper arm), same storage: refrigerated between 2°C and 8°C until you open it. A lot of people keep it in the fridge door alongside everyday items, out of direct light, easy to remember. Once in use, refer to the Patient Information Leaflet for the exact room-temperature window, because that detail matters and it can vary.

The concentration across the Wegovy titration range stays constant at 1 mg per ml, so the 0.5 mg Wegovy pen delivers 0.5 ml of solution, which is why the pen name reads "0.5 mg/0.5 ml". You're not getting a stronger formulation; you're getting more of it. That distinction is worth understanding if you're comparing pens or reading your prescription.

Injection technique doesn't change between doses. If this is your first time seeing the pen format described in detail, the 0.5 ml pen guide covers the mechanics clearly.

Side effects at the 0.5 mg step: what's typical and what isn't

Dose increases are the most common trigger for GI side effects with Wegovy. Nausea is the one most people mention, and it can be more noticeable in the first week or two after stepping up from 0.25 mg to 0.5 mg. Vomiting, loose stools, constipation, reflux and belching are also reported. For most people these settle without any action needed beyond smaller meals and staying well hydrated.

A smaller number of people experience effects that don't settle, or that are severe. Severe, persistent stomach pain (particularly if it spreads toward the back) warrants same-day medical attention because of the small but serious risk of pancreatitis, which the MHRA highlighted in its January 2026 Drug Safety Update on GLP-1 medicines. That's not a reason to avoid the medicine, but it is a reason to know what to look for.

Signs of an allergic reaction (rash, swelling, breathing difficulty), gallbladder symptoms or significant dehydration from prolonged vomiting or diarrhoea are also reasons to seek medical help promptly, not wait for your next scheduled check-in. Report any suspected side effects via the Yellow Card scheme, that reporting genuinely shapes future safety guidance.

How the 0.5 mg dose fits into the bigger picture of Wegovy treatment

0.5 mg is not where Wegovy's main clinical evidence sits. The STEP 1 trial that underpins NICE's appraisal of semaglutide for weight management used a 2.4 mg maintenance dose and reported around 15% average weight reduction over 68 weeks, a finding published in the New England Journal of Medicine. You won't see that kind of result at 0.5 mg, and that's expected.

What 0.5 mg does is establish the trajectory. Appetite suppression becomes more noticeable for many people at this dose, and the gradual titration exists precisely so the body acclimatises before reaching therapeutic levels. People who stay on a slower titration tend to experience fewer side effects and better long-term adherence. From 0.5 mg, the standard path continues to 1.0 mg, then 1.7 mg, then 2.4 mg, though your prescriber may slow or hold at any point based on your response. Details on the next step are covered in the 1 mg Wegovy pen guide.

If you're weighing up Wegovy against other licensed weight-loss treatments, or thinking about whether private treatment is the right route given NHS waiting lists, the weight-loss treatments overview sets out the options clearly. For questions about cost, the Wegovy cost guide explains what legitimate pricing includes and why the cheapest listing online is rarely the right measure for a prescription medicine.

Semaglutide is a prescription-only medicine. If you'd like a prescriber to review your situation and discuss which dose step is appropriate, you can start your free consultation with the nume clinical team.